Menu

Eyes, Nose as Windows to Alzheimer’s

Failing a sniff test or screening positive on an eye exam may predict people’s chances of developing the neurodegenerative disorder.

Jul 14, 2014
Kerry Grens

WIKIMEDIA, ADAMANTIOSA suite of studies presented at the ongoing Alzheimer's Association International Conference in Copenhagen offers a variety of ways to diagnose the neurodegenerative disease at early stages. In some cases, researchers worked out the chances of developing the disease among people who can’t smell certain odors, and in other studies scientists tested the utility of Alzheimer’s biomarkers in the eye.

“We envision a future where we can predict risk and then do things to lower risk,” Matthew Growdon, a medical student at Harvard Medical School and the Harvard School of Public Health who is working on a such a smell test, told the Washington Post.

Alzheimer’s sniff tests have been proposed before. The idea is that a poorer performance for odor detection could predict cognitive decline. “A loss of sense of smell does not mean you have Alzheimer's disease,” Kenneth Heilman, a professor in the department of neurology at the University of Florida College of Medicine in Gainesville, told HealthDay. “But if someone has episodic memory loss and also has a loss of smell, a degenerative disease like Parkinson’s or Alzheimer’s is a possibility.”

Just north of the nose, the eyes may also be windows into one’s cognitive state. Researchers reported at the conference two methods to detect beta amyloid protein using fluorescent tags either in the lens or the retina of the eye. According to The Guardian, “both tests showed that levels of beta-amyloid in the eye mirrored those seen in the brain by PET [positron emission tomography] imaging.”

Shaun Frost from Australia’s Commonwealth Scientific and Industrial Research Organisation who led one of the eye biomarker studies, told the Guardian, “if further research shows that our initial findings are correct, it could potentially be delivered as part of an individual's regular eye check-up. The high resolution level of our images could also allow accurate monitoring of individual retinal plaques as a possible method to follow progression and response to therapy.”

Such tests are not likely to be perfectly accurate, USA Today pointed out, but they may help determine who needs more definitive—and costly—testing. “Everyone with Alzheimer’s has beta amyloid in their brain, but not everyone with beta amyloid buildup will develop Alzheimer’s, limiting the predictive ability of some of these tests.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.